<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984711</url>
  </required_header>
  <id_info>
    <org_study_id>ML21427</org_study_id>
    <nct_id>NCT00984711</nct_id>
  </id_info>
  <brief_title>Observational Study of Rituxan in Rheumatoid Arthritis Patients in Routine Clinical Practice</brief_title>
  <official_title>A Phase IV, Post-marketing, Observational Study of Rituxan in Rheumatoid Arthritis Patients in Routine Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PerCuro Clinical Research Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PerCuro Clinical Research Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to gather data regarding the efficacy and safety of Rituxan in
      clinical practice whereby patients may present with concomitant medical conditions,
      medications as well as varying presentations of rheumatoid arthritis not always captured
      within the &quot;purer&quot; population seen in an industry sponsored clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2007</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with active rheumatoid arthritis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with active rheumatoid arthritis as defined by ACR criteria

          -  &gt; 18 years of age at time of consent

          -  Able to start RITUXAN therapy per the approved product monograph within approximately
             30 days of confirmed enrollment

        Exclusion Criteria:

          -  Known Type 1 hypersensitivity or anaphylactic reactions to murine proteins, Chinese
             Hamster Ovary cell proteins or to any component of RITXAN as per approved Product
             monograph

          -  Presence of any significant and or uncontrolled medical condition, which in the
             Investigator's opinion, precludes the use of RITUXAN as outlined in the Product
             Monograph
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Atkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PerCuro Clinical Research Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leeanna Bulinckx, RN, BScN</last_name>
    <phone>250-382-6270</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chantal Vaillancourt, RN, BScN</last_name>
    <phone>250-382-6270</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PerCuro Clinical Research Ltd.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christopher J Atkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <last_update_submitted>September 23, 2010</last_update_submitted>
  <last_update_submitted_qc>September 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Christopher Atkins MD</name_title>
    <organization>PerCuro Clinical Research Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

